| |Compound Summary for:
Also known as: Cesamet; Nabilona; Nabilonum; 51022-71-0; Nabilon; Cesamet (TN); Nabilone (USAN/INN); AC1NR4QM; SureCN33339
O3 Molecular Weight:
Nabilone is a synthetic cannabinoid with therapeutic use as an antiemetic and as an adjunct analgesic for neuropathic pain. It is a synthetic cannabinoid, which mimics the main ingredient of marijuana (THC) but it has more predictable side effects and causes no or minimal euphoria. Nabilone is not derived from the cannabis plant as is dronabinol.
In Canada, the United States, the United Kingdom and Mexico, nabilone is marketed as Cesamet. It was approved in 1985 by the United States FDA for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics. Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS.
Although it doesn't have the official indication (except in Mexico), nabilone is widely used as an adjunct therapy for chronic pain management. Numerous trials and case studies have demonstrate various benefits for condition such as fibromyalgia and multiple scerosis.
Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers ("trans"). From: DrugBank
| |Show subcontent titlesTable of Contents
| || |
Use and Manufacturing
Biomolecular Interactions and Pathways
Biological Test Results
Chemical and Physical Properties